Related Experiment Videos
Piperidones with activity against Plasmodium falciparum
Michael Saeftel1, Ramadan Salem Sarite, Tujo Njuguna
1Institute for Medical Microbiology, Immunology and Parasitology, D-53105, Bonn, Germany.
Parasitology Research
|March 22, 2006
Summary
New malaria drug targets are needed due to parasite resistance. Inhibiting hypusine biosynthesis in Plasmodium falciparum with compounds like mimosine derivatives showed significant antiplasmodial effects in vitro and in vivo.
Area of Science:
- Malariology
- Medicinal Chemistry
- Molecular Biology
Background:
- Malaria parasite resistance necessitates novel drug targets.
- Hypusine biosynthesis, involving deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DHH), is crucial for eukaryotic initiation factor 5A (eIF-5A) activation.
- DHH inhibitors effective in mammals were investigated for antiplasmodial activity.
Purpose of the Study:
- To investigate the antiplasmodial effects of DHH inhibitors.
- To identify potential new drug targets and lead compounds for malaria treatment.
Main Methods:
- Tested ciclopiroxolamine and L-mimosine for in vitro antiplasmodial activity.
- Utilized mimosine as a lead structure to synthesize and screen alkyl 4-oxo-piperidine 3-carboxylates.
- Evaluated lead compounds for in vitro and in vivo antiplasmodial efficacy.
Main Results:
- Ciclopiroxolamine and L-mimosine demonstrated in vitro antiplasmodial effects.
- Alkyl 4-oxo-piperidine 3-carboxylates exhibited potent antiplasmodial activity.
- These compounds showed efficacy in both in vitro and in vivo models.
Conclusions:
- Inhibiting hypusine biosynthesis is a viable strategy against malaria.
- Alkyl 4-oxo-piperidine 3-carboxylates are promising candidates for malaria drug development.
- Targeting the hypusine pathway offers a new avenue for combating drug-resistant malaria parasites.